Abeona Therapeutics Inc.
ABEOHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Abeona Therapeutics Inc. (ABEO) is listed under Biotechnology. The $399.0M market capitalization puts ABEO squarely in small-cap range for its industry. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Market Cap
$399.0M
Beta
1.33
P/E (TTM)
7.37
P/E (Fwd)
24.42
EPS (TTM)
$0.95
EPS (Fwd)
$0.29
ROE
71.0%
ROA
-38.9%
Cash
$168.3M
Total Debt
$23.2M
Free CF
-$56.6M
52W Change
6.2%
Annual Financials
Cash vs Debt
With $168.3M in cash and $23.2M in debt, ABEO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$56.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 71.0%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $1.4M (2022) to $5.8M (2025), reflecting a 312% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Abeona Therapeutics Inc.'s trajectory.